✦ LIBER ✦

311 Longer treatment duration with peginterferon alfa-2A (40KD) (Pegasys®) and ribavirin (Copegus®) in naive patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: Preliminary results of the teravic-4 study

✍ Scribed by J.M. Sánchez-Tapias; M. Diago; P. Escartin; J. Enriquez; R. Moreno; H. La Princesa; M. Romero-Gómez; H.U. de Valme; R. Bárcena; H. Ramón y Cajal; J. Crespo; H. Marqués Valdecilla; R. Andrade; H. Virgen Victoria; R. Pérez; M. Testillano; H. Cruces; R. Planas; R. Solá; H. Del Mar; M. García-Bengoechea; J. Garcia-Samaniego; H. Carlos auM. Berenguer III; H. La Fe; M. Montoro; J. del Olmo; H. Clinico; G. López; S. Tomé; T. Casanovas; H. Bellvitge; G. Castellanos; A. Castro; H. Juan Canalejo; J. Salmerón; M. Muñuz-Sánchez

Book ID: 119530220
Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 145 KB
Volume: 38
Category: Article
ISSN: 0270-9139
DOI: 10.1016/s0270-9139(03)80354-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

509 Sustained virological response after

509 Sustained virological response after prolonged treatment with peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in treatment-naïve patients with chronic hepatitis C and detectable HCV RNA after week 4 of therapy: teravic-4 study

✍ J.M. Sanchez-Tapias; M. Diago; P. Escartin; J. Enriquez; R. Moreno; M. Romero-Go 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 63 KB

328 Comparison of 48 or 72 weeks of trea

328 Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1

✍ Thomas Berg; M. Von Wagner; H. Hinrichsen; T. Heintges; P. Buggisch; T. Goeser; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

187 Efficacy and safety of 22 weeks of m

187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial

✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

522 Combination therapy with peginterfer

522 Combination therapy with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR)

✍ O. Weiland; M.W. Fried; S.J. Hadziyannis; G.R. Foster; D. Messinger; K. Freivoge 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 62 KB

106 International, multicenter, randomiz

106 International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (copegus®)

✍ Stefan Zeuzem; Moisés Diago; Edward Gane; Rajender Reddy; Paul Pockros; Patrizia 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

Plasma HCV-RNA decline in the first 48 h

Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy

✍ J. E. Arends; J. Cohen Stuart; L. C. Baak; M. E. Van Der Ende; K. J. Van Erpecum 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB